Evidence map›Paper›PMID 38651137›Full record

ArticleOpen forum infectious diseases2024

Hepatitis C Virus Antiviral Drug Resistance and Salvage Therapy Outcomes Across Australia.

Dao Sen Wang, Amy Phu, Kristen McKee, Simone I Strasser, Sinead Sheils, Martin Weltman, Sue Sellar, Joshua S Davis, Mel Young, Alicia Braund and 35 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

45 authors at 20 institutions in 1 country.

Dao Sen WangStorr Liver Centre, The Westmead Institute for Medical Research, The University of Sydney and Westmead Hospital, Sydney, NSW, Australia.
Amy PhuStorr Liver Centre, The Westmead Institute for Medical Research, The University of Sydney and Westmead Hospital, Sydney, NSW, Australia.
Kristen McKeeStorr Liver Centre, The Westmead Institute for Medical Research, The University of Sydney and Westmead Hospital, Sydney, NSW, Australia.
Simone I StrasserAW Morrow Gastroenterology and Liver Centre, The University of Sydney and Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
Sinead SheilsAW Morrow Gastroenterology and Liver Centre, The University of Sydney and Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
Martin WeltmanDepartment of Gastroenterology and Hepatology, Nepean Hospital, Kingswood, NSW, Australia.
Sue SellarDepartment of Gastroenterology and Hepatology, Nepean Hospital, Kingswood, NSW, Australia.
Joshua S DavisDepartment of Infectious Diseases, University of Newcastle and John Hunter Hospital, Newcastle, NSW, Australia.
Mel YoungDepartment of Infectious Diseases, University of Newcastle and John Hunter Hospital, Newcastle, NSW, Australia.
Alicia BraundDepartment of Gastroenterology and Hepatology, Gold Coast University Hospital, Southport, QLD, Australia.
Geoffrey C FarrellDepartment of Gastroenterology and Hepatology, Australian National University and The Canberra Hospital, Canberra, ACT, Australia.
Anne BlunnDepartment of Gastroenterology and Hepatology, Australian National University and The Canberra Hospital, Canberra, ACT, Australia.
Damian HardingDepartment of Gastroenterology and Hepatology, Lyell McEwin Hospital, Elizabeth Vale, SA, Australia.
Lucy RaltonDepartment of Gastroenterology and Hepatology, Lyell McEwin Hospital, Elizabeth Vale, SA, Australia.
Kate MullerDepartment of Gastroenterology and Hepatology, Flinders Medical Centreand Flinders University, Adelaide, SA, Australia.
Scott A DavisonDepartment of Gastroenterology and Hepatology, University of New South Wales and Liverpool Hospital, Liverpool, NSW, Australia.
David ShawDepartment of Infectious Diseases, Royal Adelaide Hospital, Adelaide, SA, Australia.
Marnie WoodInfectious Diseases Unit, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
Krispin HajkowiczInfectious Diseases Unit, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
Richard SkolenInfectious Diseases Unit, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
Jane DaviesMenzies School of Health Research and Royal Darwin Hospital, Darwin, NT, Australia.
Jaclyn Tate-BakerMenzies School of Health Research and Royal Darwin Hospital, Darwin, NT, Australia.
Adam DoyleDepartment of Gastroenterology and Hepatology, Royal Perth Hospital, Perth, WA, Australia.
Rhoda TumaDepartment of Gastroenterology and Hepatology, Royal Perth Hospital, Perth, WA, Australia.
Simon HazeldineDepartment of Gastroenterology and Hepatology, Fiona Stanley Hospital, Murdoch, WA, Australia.
Wendy LamDepartment of Gastroenterology and Hepatology, Fiona Stanley Hospital, Murdoch, WA, Australia.
Natalie EdmistonDepartment of Gastroenterology and Hepatology, School of Medicine, Western Sydney University, Sydney, NSW, Australia.
Krista ZohrabDepartment of Gastroenterology and Hepatology, School of Medicine, Western Sydney University, Sydney, NSW, Australia.
William PrattDepartment of Medicine, Shoalhaven Hospital, Nowra, NSW, Australia.
Belinda WatsonDepartment of Medicine, Shoalhaven Hospital, Nowra, NSW, Australia.
Amany ZekryDepartment of Gastroenterology and Hepatology, St George Hospital, Kogarah, NSW, Australia.
Carlie StephensDepartment of Gastroenterology and Hepatology, St George Hospital, Kogarah, NSW, Australia.
Paul J ClarkRockhampton Blood Borne Virus & Sexual Health Service and School of Medicine, University of Brisbane, Brisbane, QLD, Australia.
Melany DayRockhampton Blood Borne Virus & Sexual Health Service and School of Medicine, University of Brisbane, Brisbane, QLD, Australia.
Gordon ParkDepartment of Gastroenterology and Hepatology, Royal North Shore Hospital, St Leonards, NSW, Australia.
Hami KimDepartment of Gastroenterology and Hepatology, Royal North Shore Hospital, St Leonards, NSW, Australia.
Mark WilsonDepartment of Gastroenterology and Hepatology, Royal Hobart Hospital, Hobart, TAS, Australia.
Bruce McGarityBathurst Liver Clinic, Bathurst, NSW, Australia.
Natalie MenziesBathurst Liver Clinic, Bathurst, NSW, Australia.
Darren RussellCairns Sexual Health Service and James Cook University Cairns, St Cairns City, QLD, Australia.
Thao LamDepartment of Drug Health, Western Sydney Local Health District, Westmead, NSW, Australia.
Peter BoydDepartment of Medicine, Cairns Hospital, Cairns, QLD, Australia.
Jen KokCentre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology-Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, NSW, Australia.
Jacob GeorgeStorr Liver Centre, The Westmead Institute for Medical Research, The University of Sydney and Westmead Hospital, Sydney, NSW, Australia.
Mark W DouglasStorr Liver Centre, The Westmead Institute for Medical Research, The University of Sydney and Westmead Hospital, Sydney, NSW, Australia.ORCID https://orcid.org/0000-0003-4621-3485
The University of Sydney · AURoyal Brisbane and Women's Hospital · AUAustralian National University · AUCairns Hospital · AUFiona Stanley Hospital · AUJohn Hunter Hospital · AULyell McEwin Hospital · AUMenzies School of Health Research · AUNepean Hospital · AURoyal North Shore Hospital · AURoyal Perth Hospital · AUShoalhaven District Memorial Hospital · AUSt George Hospital · AUWestern Sydney University · AUFlinders University · AUGold Coast Hospital · AULiverpool Hospital · AURoyal Adelaide Hospital · AURoyal Hobart Hospital · AUSydney Local Health District · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hepatitis C virus (HCV) infection can now be cured with well-tolerated direct-acting antiviral (DAA) therapy. However, a potential barrier to HCV elimination is the emergence of resistance-associated substitutions (RASs) that reduce the efficacy of antiviral drugs, but real-world studies assessing the clinical impact of RASs are limited. Here, an analysis of the impact of RASs on retreatment outcomes for different salvage regimens in patients nationally who failed first-line DAA therapy is reported. Methods: We collected data from 363 Australian patients who failed first-line DAA therapy, including: age, sex, fibrosis stage, HCV genotype, NS3/NS5A/NS5B RASs, details of failed first-line regimen, subsequent salvage regimens, and treatment outcome. Results: Of 240 patients who were initially retreated as per protocol, 210 (87.5%) achieved sustained virologic response (SVR) and 30 (12.5%) relapsed or did not respond. The SVR rate for salvage regimens that included sofosbuvir/velpatasvir/voxilaprevir was 94.3% (n = 140), sofosbuvir/velpatasvir 75.0% (n = 52), elbasvir/grazoprevir 81.6% (n = 38), and glecaprevir/pibrentasvir 84.6% (n = 13). NS5A RASs were present in 71.0% (n = 210) of patients who achieved SVR and in 66.7% (n = 30) of patients who subsequently relapsed. NS3 RASs were detected in 20 patients (20%) in the SVR group and 1 patient in the relapse group. NS5B RASs were observed in only 3 patients. Cirrhosis was a predictor of relapse after retreatment, as was previous treatment with sofosbuvir/velpatasvir. Conclusions: In our cohort, the SVR rate for sofosbuvir/velpatasvir/voxilaprevir was higher than with other salvage regimens. The presence of NS5A, NS5B, or NS3 RASs did not appear to negatively influence retreatment outcomes.

Indexed as

antimicrobial resistanceantiviral therapydirect acting antiviralsdrug resistanceHepatitis C

Identifiers

PMID38651137
PMCPMC11034952
OpenAlexW4392925928

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.